Evidence map›Paper›PMID 29890946›Full record

ArticleBMC nephrology2018

Non-recovery from dialysis-requiring acute kidney injury and short-term mortality and cardiovascular risk: a cohort study.

Benjamin J Lee, Chi-Yuan Hsu, Rishi V Parikh, Thomas K Leong, Thida C Tan, Sophia Walia, Kathleen D Liu, Raymond K Hsu, Alan S Go

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMC nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05272878 (Impact of a Treatment With Angiotensin Receptor Blocker on Outcome After Acute Kidney Injury in Patients Discharged From the ICU "START-or-NOT Trial". A Prospective, Randomized, Double Blinded, Multicenter Study), which is not on this map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05272878 phase3active not recruitingnot on this mapstarted 2022, after this paper: background citation

Impact of a Treatment With Angiotensin Receptor Blocker on Outcome After Acute Kidney Injury in Patients Discharged From the ICU "START-or-NOT Trial". A Prospective, Randomized, Double Blinded, Multicenter Study

TypeinterventionalSponsorAssistance Publique - Hôpitaux de ParisRan2022 to 2026Enrolled508ConditionsAcute Kidney InjuryArmsIRBESARTAN, tablet, 150 mg, Placebo, tablet, 150 mg
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. [Prognosis of in hospital nonagenarians with acute kidney injury].Anales del sistema sanitario de Navarra · 2021
    Article
  13. Review
  14. Observational
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Benjamin J LeeDivision of Nephrology, Department of Medicine, University of California, San Francisco, San Francisco, CA, 94143, USA. bjlee@ucsf.edu.ORCID 0000-0001-6171-5091
Chi-Yuan HsuDivision of Nephrology, Department of Medicine, University of California, San Francisco, San Francisco, CA, 94143, USA.
Rishi V ParikhDivision of Research, Kaiser Permanente Northern California, Oakland, CA, 94612, USA.
Thomas K LeongDivision of Research, Kaiser Permanente Northern California, Oakland, CA, 94612, USA.
Thida C TanDivision of Research, Kaiser Permanente Northern California, Oakland, CA, 94612, USA.
Sophia WaliaDivision of Research, Kaiser Permanente Northern California, Oakland, CA, 94612, USA.
Kathleen D LiuDivision of Nephrology, Department of Medicine, University of California, San Francisco, San Francisco, CA, 94143, USA.
Raymond K HsuDivision of Nephrology, Department of Medicine, University of California, San Francisco, San Francisco, CA, 94143, USA.
Alan S GoDivision of Research, Kaiser Permanente Northern California, Oakland, CA, 94612, USA.
Kaiser Permanente · USUniversity of California, San Francisco · US

Funding

Academic Training Program in NephrologyT32DK007219 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSU, CHI-YUAN · 1986 to 2022
$7.3M
Identifying opportunities to lower rates of AKI and improve outcomesR01DK101507 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GO, ALAN S, HSU, CHI-YUAN · 2014 to 2017
$2.1M
Acute Kidney Injury: A Novel Risk Factor for Cardiovascular EventsR01DK098233 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIU, KATHLEEN D · 2014 to 2017
$1.9M
Patient Oriented Research in Kidney DiseaseK24DK092291 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSU, CHI-YUAN · 2011 to 2020
$1.2M
Advancing acute kidney injury phenotyping using biological and clinical criteriaK24DK113381 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIU, KATHLEEN D · 2017 to 2021
$915k
Enhancing appreciation of the clinical significance of acute kidney injuryK23DK100468 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSU, RAYMOND · 2013 to 2017
$892k
Clinical Outcomes after Dialysis-Requiring Acute Kidney InjuryR03DK111881 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSU, RAYMOND · 2017 to 2018
$159k
Recovery after dialysis-requiring acute kidney injuryF32DK115030 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEE, BENJAMIN JIAWEI · 2017 to 2017
$79k
NIDDK NIH HHS F32 DK115030NIDDK NIH HHS K23 DK100468NIDDK NIH HHS K24 DK092291NIDDK NIH HHS K24 DK113381NIDDK NIH HHS R01 DK098233NIDDK NIH HHS R01 DK101507NIDDK NIH HHS R03 DK111881NIDDK NIH HHS T32 DK007219
6 · The paper itself

Abstract

backgroundThe high mortality and cardiovascular disease (CVD) burden in patients with end-stage renal disease (ESRD) is well-documented. Recent literature suggests that acute kidney injury is also associated with CVD. It is unknown whether patients with incident ESRD due to dialysis-requiring acute kidney injury (AKI-D) are at higher short-term risk for death and CVD events, compared with incident ESRD patients without preceding AKI-D. Few studies have examined the impact of recovery from AKI-D on subsequent CVD risk.

methodsIn this retrospective cohort study, we evaluated adult members of Kaiser Permanente Northern California who initiated dialysis from January 2009 to September 2015. Preceding AKI-D and subsequent outcomes of death and CVD events (acute coronary syndrome, heart failure, ischemic stroke or transient ischemic attack) were identified from electronic health records. We performed multivariable Cox regression models adjusting for demographics, comorbidities, medication use, and laboratory results.

resultsCompared to incident ESRD patients who experienced AKI-D (n = 1865), patients with ESRD not due to AKI-D (n = 3772) had significantly lower adjusted rates of death (adjusted hazard ratio [aHR] 0.56, 95% CI: 0.47-0.67) and heart failure hospitalization (aHR 0.45, 0.30-0.70). Compared to AKI-D patients who did not recover and progressed to ESRD, AKI-D patients who recovered (n = 1347) had a 30% lower adjusted relative rate of death (aHR 0.70, 0.55-0.88).

conclusionsPatients who transition to ESRD via AKI-D are a high-risk subgroup that may benefit from aggressive monitoring and medical management, particularly for heart failure. Recovery from AKI-D is independently associated with lower short-term mortality.

Indexed as

Acute Kidney InjuryAgedAged, 80 and overCardiovascular DiseasesCohort StudiesFemaleFollow-Up StudiesHumansKidney Failure, ChronicMaleMiddle AgedMortalityRecovery of FunctionRenal DialysisRetrospective StudiesRisk FactorsCardiovascular eventsDialysis-requiring acute kidney injuryEnd-stage renal diseaseMortalityRenal recovery

Identifiers

PMID29890946
PMCPMC5996504
OpenAlexW2808377111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.